medigraphic.com
Instituto Nacional de Neurología y Neurocirugía

2021, Número 2

<< Anterior Siguiente >>

Arch Neurocien 2021; 26 (2)


Factores asociados con el rendimiento cognitivo en residentes de centros de cuidados a largo plazo en el Noreste de México

Coindreau-Frías F, Fernández-Garza LE, Botello-González L,Rodríguez-Fuentes DE, Barrera-Barrera SA, Barrera-Saldaña HA

Idioma: Ingles.
Referencias bibliográficas: 67
Paginas: 10-19
Archivo PDF: 280.05 Kb.


RESUMEN

Objetivo: Investigar factores asociados con deterioro cognitivo (DC) en adultos mayores mexicanos institucionalizados.
Material y métodos: Estudio transversal de residentes de tres instituciones de cuidados a largo plazo en Monterrey, México. Se realizó historia clínica, Mini-Examen del Estado Mental (MMSE), índice de Barthel, escala de depresión geriátrica y tamizaje nutricional. El DC se definió como MMSE ≤24.
Resultados: De 280 residentes octogenarios (72.1% mujeres) 61.1% tenían MMSE ≤24. Edad mayor (OR = 1,047), dependencia funcional (OR = 10,309), desnutrición (OR = 2,202), incontinencia urinaria (OR = 2,588) y antecedente de fractura (OR = 1,764) se asociaron directamente con el DC. Mayor nivel educativo (OR = 0.583) y uso de fármacos antihipertensivos (OR = 0.521), antihistamínicos (OR = 0.322), antihipertrofia de próstata (OR = 0.219) e hipolipemiantes (OR = 0.575) se asociaron inversamente.
Conclusiones: La alta prevalencia de DC y su asociación con otras enfermedades crónicas y uso de medicamentos que encontramos en la población de adultos mayores mexicanos institucionalizados, demanda la implementación de medidas que ayuden en la identificación oportuna de todas estas condiciones.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. CONAPO. Población a Inicio de año. Proyecciones de la Población de México y de las Entidades Federativas, 2016-2050. 2018.https:// datos.gob.mx/busca/dataset/proyecciones-de-la-poblacion-demexico- y-de-las-entidades-federativas-2016-2050.

  2. INMUJERES. Situación de las personas adultas mayores en México. 2015. http://cedoc.inmujeres.gob.mx/documentos_ download/101243_1.pdf.

  3. CONAPO. Proyecciones de la población de México y de las entidades federativas, 2016-2050: Nuevo León. 2019. https://www. gob.mx/cms/uploads/attachment/file/487384/19_NLE.pdf.

  4. Coindreau-Frias F, Ramos-Bacco M, et al. Características del adulto mayor institucionalizado en el área metropolitana de Monterrey. Salud Pública de México 2018; 60:738.

  5. Montes de Oca V, Hebrero M. Family dynamics, aging, and functional impairment in Mexico. Rev Kairos 2008; 11(1):143–66.

  6. Giri M, Chen T, Yu W, Lü Y. Prevalence and correlates of cognitive impairment and depression among elderly people in the world’s fastest growing city, Chongqing, People’s Republic of China. Clin Interven Aging 2016; 11:1091–98. doi: 10.2147/CIA. S113668. eCollection 2016

  7. Ren L, Zheng Y, Wu L, Gu Y, He Y, Jiang B, et al. Investigation of the prevalence of Cognitive Impairment and its risk factors within the elderly population in Shanghai, China. Sci Rep 2018; 8(1):3575. doi: 10.1038/s41598-018-21983-w

  8. Borrás Blasco C, Viña Ribes J. Neurofisiología y envejecimiento. Concepto y bases fisiopatológicas del deterioro cognitivo. Rev Esp Geriatr Gerontol 2016; 51:3-6. DOI:10.1016/ S0211-139X(16)30136-6

  9. Jakavonyté-Akstiniené A, Dikčius V, Macijauskiené J. Prognosis of treatment outcomes by cognitive and physical scales. Open Med 2018;13:74–82. doi: 10.1515/med-2018-0011

  10. Langa KM, Levine DA. The Diagnosis and Management of Mild Cognitive Impairment. JAMA 2014; 312(23):2551. doi: 10.1001/jama.2014.13806

  11. Pérez-Hernández MG, Velasco-Rodríguez R, Maturano-Melgoza JA, Hilerio-López AG, García-Hernández ML, García-Jiménez MA. Cognitive impairment and risk of falling in institutionalized older adults in the state of Colima, Mexico. Rev Enferm Inst Mex Seguro Soc 2018; 26(3):171–178.

  12. Li J, Wang YJ, Zhang M, Xu ZQ, Gao CY, Fang CQ, et al. Vascular risk factors promote conversion from mild cognitive impairment to Alzheimer disease. Neurol 2011; 76(17):1485- 91. doi: 10.1212/WNL.0b013e318217e7a4

  13. Byers AL, Yaffe K. Depression and risk of developing dementia. Nat Rev Neurol 2011;7(6):323-331. doi: 10.1038/nrneurol.2011.60

  14. Vetrano DL, Villani ER, Grande G, et al. Association of Polypharmacy With 1-Year Trajectories of Cognitive and Physical Function in Nursing Home Residents: Results From a Multicenter European Study. J Ame Med Direct Assoc. 2018;19(8):710-713. DOI: 10.1016/j.jamda.2018.04.008

  15. Sgrò G, Caruso C, Ceravolo F, Curinga G, Renda GF, Rispoli V, et al. Relationship between cognitive impairment and nutritional assessment on functional status in Calabrian long-term-care. Clin Intervent Aging 2014;105. DOI: 10.2147/CIA.S54611

  16. Deckers K, Nooyens A, van Boxtel M, Verhey F, Verschuren M, Köhler S. Gender and Educational Differences in the Association between Lifestyle and Cognitive Decline over 10 Years: The Doetinchem Cohort Study. JAD 2019;70(s1):31-41. DOI: 10.3233/JAD-180492

  17. Viswanathan A, Rocca WA, Tzourio C. Vascular risk factors and dementia: How to move forward?. Neurol. 2009; 72(4):368- 374. DOI: 10.1212/01.wnl.0000341271.90478.8e

  18. Koyanagi A, Lara E, Stubbs B, Carvalho AF, Oh H, Stickley A, et al. Chronic Physical Conditions, Multimorbidity, and Mild Cognitive Impairment in Low- and Middle-Income Countries. J Am Geriatr Soc 2018; 66(4):721-727. doi: 10.1111/jgs.15288

  19. Shen Z, Ruan Q, Yu Z, Sun Z. Chronic kidney disease-related physical frailty and cognitive impairment: a systematic review. Geriatr Gerontol Int 2017; 17(4):529-544. DOI: 10.1111/ggi.12758

  20. Dubé CE, Mack DS, Hunnicutt JN, Lapane KL. Cognitive Impairment and Pain Among Nursing Home Residents With Cancer. J Pain Symptom Management 2018;55(6):1509–1518. DOI: 10.1016/j.jpainsymman.2018.02.012

  21. Folstein MF, Folstein SE, McHugh PR. “Mini-Mental State” A practical state method for grading the cognitive state of patients for the clinician. J Psychiat Res 1975;12:189–198. DOI: 10.1016/0022-3956(75)90026-6

  22. Sainsbury A, Gudrun S, Bansal A, Young JB. Reliability of the Barthel Index when used with older people. Age and Ageing 2005;34:228–232. DOI: 10.1093/ageing/afi063

  23. Wancata J, Alexandrowicz R, Marquart B, Weiss M, Friedrich F. The criterion validity of the Geriatric Depression Scale: a systematic review. Acta Psychiatr Scand. 2006; 114(6):398-410. DOI: 10.1111/j.1600-0447.2006.00888.x

  24. Guigoz Y, Lauque S, Vellas BJ. Identifying the elderly at risk for malnutrition. Clin Geriat Med 2002; 18(4):737-757. DOI: 10.1016/s0749-0690(02)00059-9

  25. Jakavonytè-Akstinienè A, Dikčius V, Macijauskienè J. Prognosis of treatment outcomes by cognitive and physical scales. Open Med 2018;74–82. DOI: 10.1515/med-2018-0011

  26. Gallardo-Prieto L, Nellen-Hummel H, Hamui-Sutton A, et al. Valoración perioperatoria en el anciano. Cir Ciruj. 2005; 73:59–68.

  27. Prince M, Albanese E, Guerchet M, Prina M. World Alzheimer Report 2014. Dementia and Risk Reduction 2014;1–99. https:// www.alzint.org/u/WorldAlzheimerReport2014.pdf

  28. Miu J, Negin J, Salinas-Rodriguez A, Manrique-Espinoza B, Sosa- Ortiz AL, Cumming R, et al. Factors associated with cognitive function in older adults in Mexico Factors associated with cognitive function in older adults in Mexico. Global Health Action 2016;9:1–6. doi: 10.3402/gha.v9.30747

  29. Gard T, Hölzel BK, Lazar SW. The potential effects of meditation on age-related cognitive decline: a systematic review. Ann NY Acad Sci 2014;1307(1):89-103. DOI: 10.1111/nyas.12348

  30. Fulop GA, Tarantini S, Yabluchanskiy A, et al. Role of age-related alterations of the cerebral venous circulation in the pathogenesis of vascular cognitive impairment. Am J Physiol Heart Circulat Physiol 2019; 316(5):H1124-H1140. https://doi.org/10.1152/ajpheart.00776.2018

  31. Alley D, Suthers K, Crimmins E. Education and Cognitive Decline in Older Americans. Res Aging 2007; 29(1):73-94. DOI: 10.1177/0164027506294245

  32. Stern Y. Cognitive reserve in ageing and Alzheimer's disease. Lancet Neurol. 2012; 11(11):1006-1012. DOI: 10.1016/ S1474-4422(12)70191-6

  33. Black SA, Rush RD. Cognitive and Functional Decline in Adults Aged 75 and Older. Journal of the American Geriatrics Society 2002; 50(12):1978–1986. DOI: 10.1046/j.1532-5415.2002.50609.x

  34. Samus QM, Mayer L, Onyike CU, Brandt J, Baker A, Mcnabney M, et al. Correlates of Functional Dependence Among Recently Admitted Assisted Living Residents With and Without Dementia. J Ame Med Dir Assoc 2020;10(5):323–329. doi: 10.1016/j. jamda.2009.01.004

  35. Agüero-Torres H, Fratiglioni L, Guo Z, Viitanen M, Von Strauss E, Winblad B. Dementia Is the Major Cause of Functional Dependence in the Elderly: 3-Year Follow-up Data From a Population-Based Study. Am J Pub Health 1998; 88(10):1452– 1456. DOI: 10.2105/ajph.88.10.1452

  36. Millán-Calenti JC, Tubío J, Pita-Fernández S, Rochette S, Lorenzo T, Maseda A. Cognitive impairment as predictor of functional dependence in an elderly sample. Archiv Gerontol Geriatr 2012; 54(1):197-201. DOI: 10.1016/j.archger.2011.02.010

  37. Ishizaki T, Yoshida H, Suzuki T, Watanabe S, Niino N, Ihara K, et al. Effects of cognitive function on functional decline among community-dwelling non-disabled older Japanese. Archiv Gerontol Geriatr 2006; 42(1):47–58. DOI: 10.1016/j. archger.2005.06.001

  38. Zekry D, Herrmann FR, Grandjean R, Meynet M, Michel J, Gold G, et al. Demented versus non-demented very old inpatients: the same comorbidities but poorer functional and nutritional status. Age and Ageing 2008; 37(1):83-89. DOI: 10.1093/ageing/ afm132

  39. Guigoz Y, Lauque S, Vellas BJ. Identifying the elderly at risk for malnutrition. Clinics in Geriatric Medicine 2002;18(4):737-757. DOI: 10.1016/s0749-0690(02)00059-9

  40. Orsitto G, Fulvio F, Tria D, Turi V, Venezia A, Manca C. Nutritional status in hospitalized elderly patients with mild cognitive impairment. Clinical Nutrition 2006; 28(1):100–2. DOI: 10.1016/j.clnu.2008.12.001

  41. Perneczky R, Pohl C, Sorg C, Hartmann J, Tosic N, Grimmer T, et al. Impairment of activities of daily living requiring memory or complex reasoning as part of the MCI syndrome. Int J Geriat Psychiatry 2006; 21(2):158-162. DOI: 10.1002/gps.1444

  42. Shawky Khater M, Fawzy Abouelezz N. Nutritional status in older adults with mild cognitive impairment living in elderly homes in Cairo, Egypt. J Nutr Health Aging 2011;15(2):104–8. DOI: 10.1007/ s12603-011-0021-9

  43. Donini LM, De Felice MR, Cannella C. Nutritional status determinants and cognition in the elderly. Arch Gerontol Geriatr. 2007;44(S1);143–153. DOI: 10.1016/j.archger.2007.01.022

  44. de Groat WC, Griffiths D, Yoshimura N. Neural control of the lower urinary tract. Compr Physiol 2015; 5(1):327-396. doi: 10.1002/ cphy.c130056

  45. Chiang C, Wu M, Ho C, Weng S, Huang C, Hsieh W, et al. Lower Urinary Tract Symptoms Are Associated with Increased Risk of Dementia among the Elderly: A Nationwide Study. BioMed Research International 2015:1-7. doi: 10.1155/2015/187819

  46. Parthasarathy S, Fitzgerald M, Goodwin JL, et al. Nocturia, sleep-disordered breathing, and cardiovascular morbidity in a community-based cohort. PloS One. 2012; 7(2)e30969. DOI: 10.1371/journal.pone.0030969

  47. Justin BN, Turek M, Hakim AM. Heart disease as a risk factor for dementia. Clin Epidemiol. 2013; 5:135-145. doi: 10.2147/CLEP. S30621

  48. Uusi-Rasi K, Karinkanta S, Tokola K, Kannus P, Sievänen H. Bone Mass and Strength and Fall-Related Fractures in Older Age. Journal Osteoporosis 2019:1-6. https://doi. org/10.1155/2019/5134690

  49. Seitz DP, Adunuri N, Gill SS, Rochon PA. Prevalence of Dementia and Cognitive Impairment Among Older Adults With Hip Fractures. J Ame Med Director Assoc 2011; 12(8):556-564. DOI: 10.1016/j.jamda.2010.12.001

  50. Laudisio A, Fontana DO, Rivera C, Ruggiero C, Bandinelli S, Gemma A, et al. Bone Mineral Density and Cognitive Decline in Elderly Women: Results from the InCHIANTI Study. Calcif Tissue Int 2016;98(5):479-488. doi: 10.1007/s00223-015-0102-6

  51. Kang HG, Park HY, Ryu HU, Suk S. Bone mineral loss and cognitive impairment. Medicine 2018; 97(41):e12755. DOI: 10.1097/MD.0000000000012755

  52. Xu G, Bai F, Lin X, Wang Q, Wu Q, Sun S, et al. Association between Antihypertensive Drug Use and the Incidence of Cognitive Decline and Dementia: A Meta-Analysis of Prospective Cohort Studies. BioMed Research International 2017:1–11. doi: 10.1155/2017/4368474

  53. Zhuang S, Li J, Wang X, Wang H-F, Zhang W-J, Wang H-Y, et al. Renin–angiotensin system-targeting antihypertensive drugs and risk of vascular cognitive impairment: A meta-analysis. Neuroscience Letters 2016;615:1–8. DOI: 10.1016/j. neulet.2016.01.011

  54. Rouch L, Cestac P, Hanon O, Cool C, Helmer C, Bouhanick B, et al. Antihypertensive Drugs, Prevention of Cognitive Decline and Dementia: A Systematic Review of Observational Studies, Randomized Controlled Trials and Meta-Analyses, with Discussion of Potential Mechanisms. CNS Drugs 2015;29(2):113–130. DOI: 10.1007/s40263-015-0230-6

  55. Schultz BG, Patten DK, Berlau DJ. The role of statins in both cognitive impairment and protection against dementia: a tale of two mechanisms. Translational Neurodegeneration 2018;7(5). DOI: 10.1186/s40035-018-0110-3

  56. Gupta A, Thompson D, Whitehouse A, Collier T, Dahlof B, Poulter N, et al. Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase. The Lancet 2017;389(10088):2473– 2481. DOI: 10.1016/S0140-6736(17)31075-9

  57. Giugliano RP, Mach F, Zavitz K, Kurtz C, Im K, Kanevsky E, et al. Cognitive Function in a Randomized Trial of Evolocumab. New England Journal of Medicine 2017;377(7):633–643. DOI: 10.1056/NEJMoa1701131

  58. Ziad A, Olekhnovitch R, Ruiz F. Anticholinergic drug use and cognitive performances in middle age: findings from the CONSTANCES cohort. Journal of Neurology, Neurosurgery & Psychiatry 2018;89:1107-1115. DOI: 10.1136/ jnnp-2018-318190

  59. Kay GG, Harris AG. Loratadine: a non-sedating antihistamine. Review of its effects on cognition, psychomotor performance, mood and sedation. Clinical & Experimental Allergy 1999;29:147–150. DOI: 10.1046/j.1365-2222.1999.0290s3147.x

  60. Cenzer I, Nkansah-Mahaney N, Wehner M, Chren M, Berger T, Covinsky K, et al. A multiyear cross-sectional study of U.S. national prescribing patterns of first-generation sedating antihistamines in older adults with skin disease. British Journal of Dermatology 2019;182(3):763–769. DOI: 10.1111/bjd.18042

  61. Kay GG. The effects of antihistamines on cognition and performance. Journal of Allergy and Clinical Immunology 2000;105(6). DOI: 10.1067/mai.2000.106153

  62. Catalano A, Martino G, Bellone F, Papalia M, Lasco C, Basile G, et al. Neuropsychological Assessment in Elderly Men with Benign Prostatic Hyperplasia Treated with Dutasteride. Clin Drug Investig 2019;39(1):97-102. DOI: 10.1007/s40261-018-0720-7

  63. Ulrich S. Relationship found between tamsulosin and dementia Differential prescription behavior in benign prostatic syndrome may explain relationship found between tamsulosin and dementia. Pharmacoepidemiology and Drug Safety 2018;1–2. DOI: 10.1002/pds.4666

  64. Hoben M, Heninger A, Holroyd-Leduc J, Knopp-Sihota J, Estabrooks C, Goodarzi Z. Depressive symptoms in long term care facilities in Western Canada: a cross sectional study. BMC Geriatrics 2019;19(1).

  65. Han F, Bonnett T, Brenowitz WD, Teylan MA, Besser LM, Chen Y-C, et al. Estimating associations between antidepressant use and incident mild cognitive impairment in older adults with depression. Plos One 2020;15(1). DOI: 10.1371/journal. pone.0227924

  66. Prado CE, Watt S, Crowe SF. A meta-analysis of the effects of antidepressants on cognitive functioning in depressed and nondepressed samples. Neuropsychology Review 2018;28(1):32–72. DOI: 10.1007/s11065-018-9369-5

  67. Aarsland D, Bronnick K, Williams-Gray C, Weintraub D, Marder K, Kulisevsky J, et al. Mild cognitive impairment in Parkinson disease: A multicenter pooled analysis. Neurology 2010;75(12):1062– 1069. DOI: 10.1212/WNL.0b013e3181f39d0e




2020     |     www.medigraphic.com